Novartis' Afinitor fails in late-stage liver cancer study

Novartis' (NVS) Afinitor drug failed to extend the survival of patients with advanced liver cancer vs a placebo in a Phase III trial.

However, Novartis intends to continue to study Afinitor (also known as everolimus) for use in treating other cancers, including for gastrointestinal, lung and breast tumors.

Afinitor is already approved for some cancers such as advanced renal cell and pancreatic tumors. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs